Nanobiotix jumps after positive early-stage data for skin cancer therapy

** U.S.-listed shares of French drug developer Nanobiotix SA NANOB.PA, NBTX.O rise 22.7% to $12.52 premarket

** Company says its experimental radiotherapy, NBTXR3, showed favorable safety and early efficacy signals in an early-stage trial

** Trial targeted a heavily pre-treated population whose cancer had progressed despite multiple prior lines of therapy - NBTX

** Company has a licensing agreement with Johnson & Johnson JNJ.N to develop NBTXR3 for treating patients with a specific type of skin melanoma who either haven't been treated with anti–PD-1 immunotherapy or failed to respond to it

** Up to last close, stock up 255.5% YTD